|SERES THERAPEUTICS, INC. filed this Form 8-K on 10/16/2017|
SER-287 overview Biologically sourced
consortium of bacterial spores Orally administered Strong intellectual property protection supported by multiple patent claims covering Ulcerative Colitis, as well as regulatory data protection Hypothesized to act by modulating the dysbiotic
microbiome, reducing inflammation without immunosuppression effects1,2 Rationale for development supported by: Preclinical results from microbiome modification in animal models of colitis Multiple randomized, placebo-controlled clinical studies
examining induction of Clinical Remission of multiple fecal microbiota transplantation in patients with Ulcerative Colitis Blander JM et al., Regulation of inflammation by microbiota interactions with the host, Nature Immunology, 2017. Lynch S and
Pedersen O, The Human Intestinal Microbiome in Health and Disease, The New England Journal of Medicine, 2016. Costello et al. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active
ulcerative colitis, Alimentary Pharmacology & Therapeutics, 2017.
© Seres Therapeutics. All Rights Reserved.